drugset / Trial / NCT02104388

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02104388 ↗

Phase 2 Completed 69 enrolled Senju Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.

Timeline

Start
2014-04-08
Primary completion
2015-08-04
Completion
2015-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject FONADELPAR Small molecule — Other

Indications